SIRT1: A Potential Therapeutic Target in Autoimmune Diseases

Front Immunol. 2021 Nov 23:12:779177. doi: 10.3389/fimmu.2021.779177. eCollection 2021.

Abstract

The morbidity and mortality of autoimmune diseases (Ads) have been increasing worldwide, and the identification of novel therapeutic strategies for prevention and treatment is urgently needed. Sirtuin 1 (SIRT1), a member of the class III family of nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases, has been reported to participate in the progression of several diseases. SIRT1 also regulates inflammation, oxidative stress, mitochondrial function, immune responses, cellular differentiation, proliferation and metabolism, and its altered functions are likely involved in Ads. Several inhibitors and activators have been shown to affect the development of Ads. SIRT1 may represent a novel therapeutic target in these diseases, and small molecules or natural products that modulate the functions of SIRT1 are potential therapeutic agents. In the present review, we summarize current studies of the biological functions of SIRT1 and its role in the pathogenesis and treatment of Ads.

Keywords: SIRT1; autoimmune diseases; inflammation; rheumatoid arthritis; systemic lupus erythematosus.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / drug effects
  • Animals
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / enzymology
  • Autoimmune Diseases / immunology
  • Autoimmunity / drug effects*
  • Enzyme Activation
  • Enzyme Activators / adverse effects
  • Enzyme Activators / therapeutic use*
  • Histone Deacetylase Inhibitors / adverse effects
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Immunity, Innate / drug effects
  • Molecular Targeted Therapy
  • Signal Transduction
  • Sirtuin 1 / antagonists & inhibitors*
  • Sirtuin 1 / metabolism

Substances

  • Enzyme Activators
  • Histone Deacetylase Inhibitors
  • SIRT1 protein, human
  • Sirtuin 1